Key Highlights
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) fell 15.4%, or USD 8.95, to USD 49.21 on November 9, 2026, from a close of USD 58.16 on November 6, on Volume nearly double its average.
- The company issued no price-sensitive announcement that day, while rival Ionis Pharmaceuticals fell about 27% after cutting its full-year Tryngolza sales forecast to about USD 50 million from USD 100 million to USD 110 million.
- Arrowhead's plozasiran, sold as Redemplo, competes directly with Tryngolza in treating very high triglycerides, so a weaker market outlook for one weighs on both.
- Pooled Phase 3 data presented on November 7 showed a 78% reduction in acute pancreatitis events, alongside worsening glycemic control in 14% of treated patients against 8.7% on placebo.
What Drove the Drop
The fall in Arrowhead Pharmaceuticals (NASDAQ:ARWR) came on a day when almost every other healthcare stock rose, which points to company-specific or read-across pressure. The clearest trigger was the forecast cut at Ionis, whose Tryngolza targets the same group of patients with familial chylomicronemia syndrome and severe hypertriglyceridemia. When a competitor halves its sales expectations for a drug in the same class, investors reassess the size of the market for every product in it, including Redemplo. No direct link between the two moves has been confirmed, but the timing and the overlap in patient groups made the read-across hard to ignore. The weekend data presentation added a second consideration, because the glycemic control signal could become a talking point with doctors weighing treatment options. Biotech stocks with a single lead commercial product are especially sensitive to such read-across, because one competitor's experience is often the best available guide to how quickly a new market will grow.
The Data and the Balance Sheet
The pooled SHASTA-3 and SHASTA-4 results, covering 757 adults, were strong on the main clinical outcome: a 78% reduction in acute pancreatitis events against placebo, a meaningful result for a condition where pancreatitis is a serious and costly complication. The imbalance in glycemic control, at 14% against 8.7%, is a safety detail that may shape label discussions and physician preference as the company seeks a wider indication. Arrowhead plans a supplemental application for severe hypertriglyceridemia by the end of 2026, which would greatly expand the eligible population. On the financing side, the company replaced an expensive Loan on November 4 with a USD 400 million Facility priced at a floating benchmark plus 5.50%, against 15% on the retired debt, and maturing in November 2031. These results support the clinical case for the drug, but commercial success will depend on how quickly doctors adopt it and how insurers decide to cover it.
Risks and What to Watch
The near-term risk is that the market for triglyceride-lowering drugs develops more slowly than expected, as the Ionis forecast suggests. Arrowhead Pharmaceuticals (NASDAQ:ARWR) differentiates on quarterly dosing compared with monthly for its rival, but prescription uptake, payer coverage and the safety profile will decide how much that advantage is worth. The next major event is the release of fiscal 2026 results, covering the year ended September 30, with a webcast on November 12, 2026, where investors will look for early Redemplo sales, launch metrics and comments on the competitive landscape. The planned filing for the larger severe hypertriglyceridemia population remains the main long-term value driver. Short-term trading may stay volatile until the company gives investors hard numbers on prescriptions and revenue.
Where Things Stand
Arrowhead fell 15.4% to USD 49.21 on November 9, 2026 with no company announcement, as Ionis cut its forecast for a competing triglyceride drug and investors weighed a glycemic signal in weekend data. The stock remains tied to the commercial outlook for Redemplo and to a planned filing in a much larger patient group. Fiscal 2026 results on November 12 are the next marker.






Please wait processing your request...